{"name":"LitePharmTech Co., Ltd.","slug":"litepharmtech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Atropine Sulfate 01","genericName":"Atropine Sulfate 01","slug":"atropine-sulfate-01","indication":"Anticholinergic toxicity and organophosphate poisoning","status":"phase_3"},{"name":"Atropine Sulfate 03","genericName":"Atropine Sulfate 03","slug":"atropine-sulfate-03","indication":"Anticholinergic poisoning and organophosphate/nerve agent exposure","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Atropine Sulfate 02","genericName":"Atropine Sulfate 02","slug":"atropine-sulfate-02","indication":"Anticholinergic poisoning and organophosphate/nerve agent exposure","status":"phase_3"}]}],"pipeline":[{"name":"Atropine Sulfate 01","genericName":"Atropine Sulfate 01","slug":"atropine-sulfate-01","phase":"phase_3","mechanism":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.","indications":["Anticholinergic toxicity and organophosphate poisoning","Bradycardia and heart block","Preoperative medication in anesthesia","Mydriasis for ophthalmic procedures"],"catalyst":""},{"name":"Atropine Sulfate 02","genericName":"Atropine Sulfate 02","slug":"atropine-sulfate-02","phase":"phase_3","mechanism":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.","indications":["Anticholinergic poisoning and organophosphate/nerve agent exposure","Symptomatic bradycardia","Mydriasis and cycloplegia for ophthalmic examination","Preoperative antisialagogue"],"catalyst":""},{"name":"Atropine Sulfate 03","genericName":"Atropine Sulfate 03","slug":"atropine-sulfate-03","phase":"phase_3","mechanism":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.","indications":["Anticholinergic poisoning and organophosphate/nerve agent exposure","Symptomatic bradycardia and heart block","Mydriasis and cycloplegia for ophthalmic examination","Reduction of salivary, bronchial, and gastric secretions perioperatively"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}